PT - JOURNAL ARTICLE AU - Michal R. Tomaszewski AU - Shuxuan Fan AU - Alberto Garcia AU - Jin Qi AU - Youngchul Kim AU - Robert A. Gatenby AU - Matthew B. Schabath AU - William D. Tap AU - Denise K. Reinke AU - Rikesh J Makanji AU - Damon R. Reed AU - Robert J. Gillies TI - Imaging-based patient inclusion model improves clinical trial performance AID - 10.1101/2021.01.18.21249895 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.18.21249895 4099 - http://medrxiv.org/content/early/2021/06/08/2021.01.18.21249895.short 4100 - http://medrxiv.org/content/early/2021/06/08/2021.01.18.21249895.full AB - Purpose Success of new cancer therapies relies strongly on effective selection of the target patient populations. We hypothesize that computational analysis of imaging data can be used for patient enrichment in clinical trials and hence aimed to establish the appropriate framework for this analysis.Methods This was tested among soft-tissue sarcoma (STS) patients accrued into a randomized clinical trial (SARC021) that evaluated the efficacy of evofosfamide (Evo), a hypoxia activated prodrug, in combination with doxorubicin (Dox). Notably, SARC021 failed to meet its overall survival (OS) objective. We tested whether a radiomic biomarker-driven inclusion/exclusion criterion could have been used to result in a significant treatment benefit of the Evo+Dox combination compared to Dox monotherapy. 164 radiomics features were extracted from 303 SARC021 patients with lung metastases, divided into training and test sets.Results A single radiomics feature, Short Run Emphasis, was identified as the most informative. Combined into a model along with histological classification and smoking history, an enriched subset (42%) of patients had longer OS in Evo+Dox vs. Dox groups [p=0.01, Hazard Ratio (HR) =0.57 (0.36-0.90)]. Applying the same model and threshold value in an independent test set confirmed the significant survival difference [p=0.002, HR=0.29 (0.13-0.63)], identifying patients most likely to benefit from doxorubicin alone.Conclusion The study presents a first of its kind clinical-radiomic approach for patient enrichment in clinical trials. We show that, had an appropriate model been used for selective patient inclusion, SARC021 trial could have met its primary survival objective for patients with metastatic STS.Competing Interest StatementRJG has a competing interest as investor with research support and advisory board appointment from HealthMyne, Inc and research support from Helix Biopharma, not related to work. DRR reports personal fees from Threshold, during the conduct of the study; travel reimbursement from Salarius, and serves on advisory board of Epizyme, both outside the submitted work. WDT reports personal fees from Eli Lilly, personal fees from EMD Serono, personal fees from Eisai, personal fees from Mundipharma, personal fees from C4 Therapeutics, personal fees from Daiichi Sankyo, personal fees from Blueprint, personal fees from GlaxoSmithKline, personal fees from Agios Pharmaceuticals, personal fees from NanoCarrier, personal fees from Deciphera, outside the submitted work; In addition, Dr. Tap has a patent Companion Diagnostic for CDK4 inhibitors - 14/854,329 pending to MSKCC/SKI and Scientific Advisory Board - Certis Oncology Solutions, Stock Ownership Co-Founder - Atropos Therapeutics, Stock Ownership. All other authors declare no conflicts of interest.Clinical TrialNCT01440088 (retrospective analysis of the trial data)Funding StatementThis work was supported by National Cancer Institute (grants U54CA193489, R01CA187532, U01CA143062, P30CA76292) and pilot funds from the Moffitt Cancer Center Department of Radiology. Dr. Fan was partially supported by funds from the Dept. Radiology, Tianjin Medical University, Tianjin, ChinaAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board at the University of South Florida approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis code and processed anonymized data may be available on request.